Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Ovid Therapeutics Inc. shareholders approved Ratification of KPMG LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-06-10 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-10
Exact text from the filing
Proposal 3 : The Company’s stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026 by the votes set forth in the table below: For Against Abstain Broker Non-Votes 130,845,667 32,505 80,756 N/A
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Ovid Therapeutics Inc. shareholders approved Advisory vote on compensation paid to named executive officers at the 2026-06-10 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-06-10
Exact text from the filing
Proposal 2: The Company’s stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers, as disclosed in the Proxy Statement, by the votes set forth in the table below: For Against Abstain Broker Non-Votes 84,511,953 8,901,691 2,334,071 35,211,213
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Ovid Therapeutics Inc. shareholders approved Election of director Jeremy M. Levin, DPhil, MB BChir for a three-year term at the 2026-06-10 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-10
Exact text from the filing
Proposal 1 : The Company’s stockholders elected the nominee for director to serve a three-year term until the Company’s 2029 annual meeting of stockholders and until his successor has been duly elected and qualified, or, if sooner, until his death, resignation or removal, by the votes set forth in the table below: Nominee For Withheld Broker Non-Votes Jeremy M. Levin, DPhil, MB BChir 87,219,707 8,528,008 35,211,213
View on SEC.gov